Novartis AG's Kisqali (ribociclib) is the first CDK4/6 inhibitor to show a significant overall survival advantage in HR+/HER2- advanced breast cancer, bolstering its position in the competitive market, where it has struggled to make substantial headway against Pfizer Inc.'s first-in-class Ibrance (palbociclib).
The positive overall survival data from the MONALEESA-7 trial were featured in a press briefing at the American Society of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?